Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d’étude des Tumeurs Endocrines) Study
| العنوان: | Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d’étude des Tumeurs Endocrines) Study |
|---|---|
| المؤلفون: | Christine Binquet, Eric Mirallié, Jean-Christophe Lifante, Cynthia Reichling, François Pattou, Pierre Goudet, Olivier Facy, Bruno Carnaille, Sébastien Gaujoux, Nicolas Santucci, Muriel Mathonnet |
| المصدر: | World Journal of Surgery |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, endocrine system diseases, Original Scientific Report, 030230 surgery, Glucagonoma, Neuroendocrine tumors, Gastroenterology, Pancreaticoduodenectomy, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Internal medicine, Multiple Endocrine Neoplasia Type 1, medicine, Humans, MEN1, Multiple endocrine neoplasia, Insulinoma, VIPoma, business.industry, medicine.disease, Pancreatic Neoplasms, Neuroendocrine Tumors, 030220 oncology & carcinogenesis, Surgery, business, Abdominal surgery |
| الوصف: | Aim To assess postoperative complications and control of hormone secretions following pancreatoduodenectomy (PD) performed on multiple endocrine neoplasia type 1 (MEN1) patients with duodenopancreatic neuroendocrine tumors (DP-NETs). Background The use of PD to treat MEN1 remains controversial, and evaluating the right place of PD in MEN1 disease makes sense. Methods Thirty-one MEN1 patients from the Groupe d’étude des Tumeurs Endocrines MEN1 cohort who underwent PD for DP-NETs between 1971 and 2013 were included. Early and late postoperative complications, secretory control and overall survival were analyzed. Results Indication for surgery was: Zollinger–Ellison syndrome (n = 18; 58%), nonfunctioning tumor (n = 9; 29%), insulinoma (n = 2; 7%), VIPoma (n = 1; 3%) and glucagonoma (n = 1; 3%). Mean follow-up was 141 months (range 0–433). Pancreatic fistulas occurred in 5 patients (16.1%), distant metastases in 6 (mean onset of 43 months; range 13–110 months), postoperative diabetes mellitus in 7 (22%), and pancreatic exocrine insufficiency in 6 (19%). Five-year overall survival was 93.3% [CI 75.8–98.3] and ten-year overall survival was 89.1% [CI 69.6–96.4]. After a mean follow-up of 151 months (range 0–433), the biochemical cure rate for MEN-1 related gastrinomas was 61%. Conclusion In MEN1 patients, pancreatoduodenectomy can be used to control hormone secretions (gastrin, glucagon, VIP) and to remove large NETs. PD was found to control gastrin secretions in about 60% of cases. |
| تدمد: | 1432-2323 0364-2313 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a42605eb9ea5a98f56f660ca5e75ecf3Test https://doi.org/10.1007/s00268-021-06005-7Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a42605eb9ea5a98f56f660ca5e75ecf3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14322323 03642313 |
|---|